Anyone else having trouble getting on Lion.com?

Anyone else jump back in SRZ today? Grabbed a bit at $2.40. Way, way oversold here.

In NCOC here. MOMO off coal stocks will drive this one.

Really great news.

Grabbing AAU on discovery news here:

Almaden Minerals Ltd. ("Almaden") (TSX: AMM)(NYSE Amex: AAU) is pleased to report that Tarsis Resources Ltd. ("Tarsis") (TSX: TCC), in which Almaden holds a roughly 27.6% interest, has received assay results from the end of the 2009 field program at the Prospector Mountain property. The 5,000 hectare Prospector Mountain project is 100% owned by Tarsis (subject to a 2% NSR held by Almaden) and located in southwestern Yukon, Canada. Exploration during the final phase of work focussed on the porphyry target in the eastern part of the project. Mapping and sampling defined an area now referred to as the Bonanza Zone. The below Table lists the most significant results for vein material collected from the Bonanza Zone, highlights of which include:

- 82.8 g/t Au, 299 g/t Ag and 1.49% Cu

- 14.0 g/t Au, 1340 g/t Ag and 11.65% Cu

- 55.7 g/t Au, 1375 g/t Ag and 7.38% Cu

- 82.2 g/t Au, 888 g/t Ag and 5.97% Cu

The gold-silver-copper showings of the Bonanza Zone occur along a 1,200 meter north northwest structural trend located near a contact between potassic altered monzonite intrusive and overlying volcanic rocks. Recessive lineaments defining the Bonanza structural trend are interpreted to span a width of roughly 200 meters. Eighteen samples of locally weathering vein talus were taken in total and results ranged from below detection to 82.8 g/t Au, below detection to 1375 g/t Ag and 3 ppm to 11.65% Cu. Some of the samples were collected specifically for fluid inclusion studies and alteration characterization. Vein talus ranging from 5 to 35 cm thickness collected from eight sites along the trend are mostly comprised of multiple pulse vuggy quartz and quartz breccia with varying combinations of accessory earthy to specular hematite, black tourmaline, hematized siderite and limonite. Some samples also contain malachite and azurite either as breccia clasts, matrix filling and or later fracture filling and rare pyrite and chalcopyrite. Most samples taken from Bonanza Zone also yielded elevated bismuth (to greater than 1%) and variably elevated arsenic (to 3490 ppm), antimony (to greater than 1%) and lead (to 2400 ppm). Exceptions within this suite of samples are: H886468 which is comprised of vuggy quartz-tourmaline and believed to be associated with a more northerly trending cross-cutting structure; and samples H886454 and H886467 which represent lower grade stockwork style veinlets hosted within altered porphyry talus. A separate gold occurrence referred to as the Hart Showing and located 1 km southwest of the Bonanza Zone, consists of a small exposure of vuggy grey silica talus with variable amounts of scorodite alteration. A sample collected from this historical exposure returned 5.61 g/t Au, 65.8 g/t Ag and 0.34% Cu. Historic copper-in-soil values along the trend are generally low but this may be largely attributed to extensive talus cover and poor soil development. The historic soil sampling programs in this part of the property did not analyse for gold, silver or accessory indicator elements useful for identifying precious metal veins.

ANX -- $1bln+ U.S. market opportunity, NO Debt, 12 months cash-on-hand...

-Large market opportunities accessible with affordable, share-shifting commercial plan
-Developing 2 products for established markets with first NDA submission in 2009
-Scalable long term business model.

Extreeeeeemely cheap here at $.12

Looking for $1-2 medium term.

Support at $.19-- if it breaks below that, consider getting out an re-entering.

This is what happens when you have no bid support. Hope some of you were smart and took profits while you had them...

Hey Chart, I haven't been 'round the University recently and I was wondering if you'd have an updated list of your holdings at any point. The most recent info in the Ibox looks to be from September. Curious to see what's new.

TIA

Disclosure: In CONN @ $8.03, in ANDS @ $2.26

Hope not everyone sold the gap on SRZ. What a run this thing is making!

In MNKD here. This one's gonna be big IMO.

Chart, how up-to-date is the ibox? I only ask because it looks like a lot of the positions WU opened are getting hammered from their entry -- FREE, BEST, OXGN, ACAS, CPF, DRRX, ISYS.

Have you closed these positions yet, or are you waiting for a reversal? Perhaps the ibox is misleading and that's where I'm confused.

Thanks,
Andrew

PTN is a screaming buy-- AstraZeneca is actually funding additional clinical studies in addition to the $5m its paying them. Chart set-up looks sweet.

In today $.335. This has double/triple written all over it IMO

In PTN on news: *PTN To Receive $5M from AstraZeneca from Amendment to License Agreement*

Palatin Technologies, Inc. (PTN) will receive $5 million from AstraZeneca (AZN) relating to an amendment of its ongoing exclusive research collaboration and license agreement to discover, develop and commercialize compounds that target melanocortin receptors for treatment of obesity and related indications.

Under the terms of the amendment to the parties' collaboration agreement, AstraZeneca has agreed to make a $2.5 million payment upon signing and, subject to completion of certain tasks relating to the program, $2.5 million in the first quarter of calendar year 2010. Under the amendment, the terms of the original collaboration and license agreement signed in January 2007 relating to milestone payments and royalty rates were restructured.

Palatin has completed an exploratory clinical study with a melanocortin receptor compound and has also agreed to conduct additional clinical studies under a clinical trial sponsored research agreement to be funded by AstraZeneca.

I can one up you-- UQ since .05, PQ since $1.35....

Good luck to all!!

Hi Chart, noticed your TAMB posts on Lion from late August and wondering what your thoughts are after Friday's drop. Think now's a good time to ride the bounce?

Here's the chart:

Jumped in DDSS here. Chart looks to be setting up nicely.

ASFX looking good in Pre-Market...

Ha, that's actually pretty funny. Thanks for posting.

Really? I did not know that. Can you provide links to PRs that recycle the same news? I'd be interested to read those...

ASFX News -- American Scientific Resources Acquires Intellectual Property to World's Only
FDA Approved Home Needle Destruction Device



WESTON, Fla., Sept. 14 /PRNewswire-FirstCall/ -- American Scientific
Resources, Inc. (Pink Sheets: ASFX) (the Company), is excited to announce that
it has acquired the intellectual property to the world's only FDA approved
home needle destruction device (NDD), the Disintegrator(TM) and Disintegrator
Plus(TM) (U.S. Patent No. 6,384,362 Patent Application No.: 09/500,504) (the
"Device Technology").

A formerly owned property of Safeguard Medical Technologies, American
Scientific Resources now holds the rights to the patent, which includes the
Device Technology Patent and all present and future developed information,
knowledge, experience and results.

As part of the agreement, all current contracts and future sales and contracts
pertaining to the Device Technology are the sole property of ASR. Rights to
such sales are worldwide with the exception of a single licensing agreement
covering the European Union region where Safeguard pays a consulting royalty
on sales.

Safeguard will receive stock, warrants, a convertible note and cash payments
based on sales performance. They will also provide ongoing production
engineering and quality control services to ASR for a fee.

ASR's plan is to introduce the product commercially in the fall/winter of
2009. The Disintegrator enables patients who give themselves injections,
including those suffering from multiple sclerosis or diabetes, to properly and
safely dispose of needles at home. The EPA and the American Diabetes
Association approve the device.

Dr. Christopher F. Tirotta, CEO of American Scientific Resources, states, "We
are overjoyed to have acquired the property rights to a product that we think
has enormous potential to be a worldwide leader in home needle destruction.
The product has already received a warm reception in the market."

Safeguard delivered a purchase order for 5000 units to one of the world's
leading healthcare enterprises in March of 2009; since then, the global
enterprise has placed an additional order for 2000 units which American
Scientific Resources will fill. Safeguard practices a form of just-in-time
productivity, matching production to its needs based on order size.
Production is planned to ramp up by year's end with full production capability
exceeding 25,000 units per month.

California State Senator Joe Simitian announced recently that his bill, SB
486, is headed to the Governor for review. The bill is designed to facilitate
the safe disposal of syringes and needles (also known as "sharps") by
requiring pharmaceutical manufacturers who sell specialty drug medications for
home use to provide information on their websites on safe needle collection
and disposal programs for their drugs. Over one million Californians who use
specialty injection drugs don't have a safe, legal way to dispose of their
sharps. Hence, approximately 386-million sharps are generated each year in
California that need to be disposed of.

"Given the need in the US for a safe way to dispose of sharps, we are hopeful
that the Disintegrator will eventually become a trusted household name,"
continues Dr. Tirotta.

Additionally, a congressional bill (S, 1312) is pending which would amend
Title XVIII of the Social Security Act to provide for coverage, as supplies
associated with the injection of insulin, of containment, removal,
decontamination, and disposal of home-generated needles, syringes, and other
sharps through a sharps decontamination/destruction device or similar program
under part D of the Medicare program.

About American Scientific Resources, Inc.
American Scientific Resources, Inc. is a holding company for two wholly owned
subsidiaries, Kidz-Med, Inc. and Heart Smart System. The Company's objective
is to locate and acquire innovative health and safety products that are
successfully sold abroad, and to introduce and promote them to the North
American market.

More information about the Company, including financial information, can be
found on the ASFX web site at www.americansci.com. For product information,
visit the Company's subsidiary, Kidz-Med, Inc. at www.kidzmed.com.

Safe Harbor
This release may contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Statements contained in this
release that are not historical facts may be deemed to be forward-looking
statements. Investors are cautioned that forward-looking statements are
inherently uncertain. Actual performance and results may differ materially
from that projected or suggested herein due to certain risks and uncertainties
including, without limitation, ability to obtain financing and regulatory and
shareholder approvals for anticipated actions.

Contact
Americansci.com
Erika Stanczak
Phone:
847-386-1384 x.201
estanczak@americansci.com

SOURCE American Scientific Resources, Inc.

Erika Stanczak, American Scientific Resources, +1-847-386-1384 x.201,
estanczak@americansci.com

Jumped in ASFX. Interesting news out today... Any targets, Chart?

Just go here:

http://www.wsw.com/webcast/rrshq15/adls.ob/

It has the full powerpoint presentation. There are a lot of great points about Restanza, CAP trials, and the likelihood of a major DOD contract to stockpile the anthrax vaccine.

You'd do well on yourself to check it out ;)

Presentation is already over. You can view the PPT slideshow on their website.

Very positive stuff...

GVBP--NEWS OUT: stem cell tech could cure breast cancer

NEW YORK, Sept. 11 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotherapeutics, Inc., ("GENova"), released important information about its innovative method for destroying breast cancer cells, using stem cell technology.

GENova's approach is based on cutting-edge technology that enables us to identify the protein expression in the original cancer stem cells that give rise to tumors. This ability to identify the molecular markers of these cells is an important first step in developing new and superior cancer cures, says John Savin, VP for GENova. "By recognizing the existence of cancer stem cells, we have taken a great step towards understanding this complex disease. Now that we know how to identify the unique characteristics of these stem cells, we can develop cell-specific therapies that can eradicate them --and thus neutralize breast cancer right at the source."

The key behind GENova's biotechnology is tracing cancer cells to their origin, the very stem cells from where the first malignant cell arose. Now that they are identifiable, scientists are developing tailor-made proteins that are programmed to destroy cancerous cells, whilst leaving the healthy cells intact. GENova has targeted these bio-engineered proteins for acquisition into its growing anti-cancer drug pipeline.

In the future, this technology will also enable us to identify healthy stem cells and then develop, inject, and nurture them in such a way that they can overcome the malignant cells. Eventually, healthy stem cells will overcome the sick cells, leaving the patient cured. This novel method for treating breast cancer is far superior to existing treatments, and is the underpinning of GENova's IP (Intellectual Property) portfolio.

Development of this important biotechnology would mean a new cure for cancer, rendering disfiguring mastectomies and harmful radiation therapies obsolete.

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies such as Pfizer, Amgen, Myriad Genetics, Medarex, and Biogen Idec. Visit GENova online at www.genovabio.com

GVBP---New stem cell technology could cure breast cancer

NEW YORK, Sept. 11 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotherapeutics, Inc., ("GENova"), released important information about its innovative method for destroying breast cancer cells, using stem cell technology.

GENova's approach is based on cutting-edge technology that enables us to identify the protein expression in the original cancer stem cells that give rise to tumors. This ability to identify the molecular markers of these cells is an important first step in developing new and superior cancer cures, says John Savin, VP for GENova. "By recognizing the existence of cancer stem cells, we have taken a great step towards understanding this complex disease. Now that we know how to identify the unique characteristics of these stem cells, we can develop cell-specific therapies that can eradicate them --and thus neutralize breast cancer right at the source."

The key behind GENova's biotechnology is tracing cancer cells to their origin, the very stem cells from where the first malignant cell arose. Now that they are identifiable, scientists are developing tailor-made proteins that are programmed to destroy cancerous cells, whilst leaving the healthy cells intact. GENova has targeted these bio-engineered proteins for acquisition into its growing anti-cancer drug pipeline.

In the future, this technology will also enable us to identify healthy stem cells and then develop, inject, and nurture them in such a way that they can overcome the malignant cells. Eventually, healthy stem cells will overcome the sick cells, leaving the patient cured. This novel method for treating breast cancer is far superior to existing treatments, and is the underpinning of GENova's IP (Intellectual Property) portfolio.

Development of this important biotechnology would mean a new cure for cancer, rendering disfiguring mastectomies and harmful radiation therapies obsolete.

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies such as Pfizer, Amgen, Myriad Genetics, Medarex, and Biogen Idec. Visit GENova online at www.genovabio.com

Scratch that. It's actually their presentation at Rodman & Renshaw thats going to be broadcast. I would expect a PR to follow...

Conference call this morning. Let's see what happens...

Thanks, Ken. We'll see what happens. Maybe not a homerun, but even $.02-$.03 would be nice compound.

Best of luck to you!

Hmmm, I think I respectfully disagree. There are a lot of fundamental and technical positives here despite it's decline since early summer. We can all site countless examples of small/micro-cap biotech pharmaceuticals which experience precipitous price drops after an FDA rejection. The FDA anticipation drives them up higher than they're worth and conversely, knocks them down to levels at which they're way undervalued. That's where ADLS is right now.

Per their recent PRs, on-going studies have shown amazing efficacy results with Restanza, as well as a close working relationship with the FDA to get this drug approved. From the perspective of the FDA, ADLS is one of the one of the only companies working on pharmaceutical solutions to bioterrorism.

I believe the chart also has a lot of technical positives, including a near $.25 gap that will eventually be filled.

Anyway, just my two cents!

ADLS is in serious accumulation mode here. Expect a huge jump in price going into next week's bio-conference!

Love to get an opinion about ADLS from you guys...

Been posting this for the last couple days and can't get a response one way or the other. This one looks like an amazing bounce/gap-fill candidate...

lol apparently i'm outvoted on this one anyway.

Hate to be nit-picky, but can we limit all the bold posts from people who aren't Chart and/or professors? You know who you are :P

ADLS was 1.50 on Jun 1, currently .215. Major gap-fill is a near certainty. Chart + news of anthrax efficacy makes this one a definite buy.

Looking for some input here-- ADLS really looks good to me, but if anyone with an experienced set of chart eyes wants to take a look, I'd appreciate it:

I'm averaged in EDAP at about $4.10. Haven't really decided what I'll do with it though. Decent chance I'll sell tomorrow AM on a gap up. Too much volatility on those Lion plays, not to mention the fact that it's already had a run of 225% in the last two weeks. I don't know how much more people can realistically expect from it in the near term. Just my opinion though!

Hey Chart-- posted this last night, but I'd love your thoughts. I really think this one has the potential to double or triple in short order.

Chart here is a thing of beauty. It's a bottom play, plain and simple and should see 100%-125% in relatively short order.

http://stockcharts.com/c-sc/sc?s=ADLS&p=D&yr=0&mn=6&dy=0&i=p57737607023&r=7025